Clinical Trials Logo

Toxicity Due to Chemotherapy clinical trials

View clinical trials related to Toxicity Due to Chemotherapy.

Filter by:

NCT ID: NCT06274268 Not yet recruiting - Sarcopenia Clinical Trials

Effect of Sarcopenia on the Occurrence of Toxicity Related to Anti-cancer Treatments

SARC-ONCO
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn about the effect of sarcopenic status on the occurrence of treatment-related toxicity during the first course of anti-cancer treatment in several types of cancers. The main question it aims to answer is : Is sarcopenia a predictive marker for the occurrence of toxicity in the initial phase of cancer treatment? The evaluation will focus on the body composition of the participants, assessed by impedancemetry, and on their muscular performance by standardized physical tests.

NCT ID: NCT05927636 Recruiting - Cancer Clinical Trials

Systemic Treatment Related Toxicity Identified With a Smartphone APPlication Measuring Step Count

STAPPS
Start date: September 1, 2022
Phase:
Study type: Observational

The goal of this observational study is to investigate whether daily physical activities measured with a smartphone are related to the possible side effects or other physical complaints that arise as a result of cancer treatment. The investigators want to test whether the number of steps per day, both before and during treatment, are related to possible side effects or other physical complaints of the treatment using a smartphone. Knowledge about this relationship gives us possible starting points to prevent and/or reduce side effects and improve treatment outcomes. Additional research would then be needed. The investigators also want to investigate whether these daily measurements are feasible for patients undergoing treatment. Participation in the study involves measuring daily physical activity from the week before treatment until the first 3 months of treatment have been completed. This is done by tracking daily steps with patients own phone using the OncoSTAPP application.

NCT ID: NCT05885048 Recruiting - Cancer Clinical Trials

Impact of Gonadotoxic Therapies on Fertility

FertiTOX
Start date: December 1, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to learn how gonadotoxic treatments (chemotherapies, radiotherapies or immunotherapies) affect the fertility status of participants with cancer. The main questions it aims to answer are: - in females, if cancer therapies reduce the Anti-Müllerian hormone (AMH) concentration (ovarian reserve); - in males, if cancer therapies reduce sperm concentration (sperm quality).

NCT ID: NCT04999332 Recruiting - Gastric Cancer Clinical Trials

Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer

LOTS
Start date: December 10, 2021
Phase: Phase 2
Study type: Interventional

The aim of the trial is to investigate the clinical efficacy and toxicity of perioperative chemotherapy with leucovorin, oxaliplatin, docetaxel and S-1 (LOTS) in patients with locally advanced gastric or gastroesophageal junction adenocarcinoma who receive a curative surgery.

NCT ID: NCT04737265 Active, not recruiting - Breast Cancer Clinical Trials

Pilot Study of an NTproBNP Guided Strategy of Cardioprotection

NTproBNP-Guide
Start date: March 18, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Investigators will evaluate the safety and feasibility of a biomarker-guided cardioprotection strategy using NTproBNP, as compared to usual care, in breast cancer and lymphoma patients treated with anthracyclines.

NCT ID: NCT04023110 Active, not recruiting - Breast Cancer Clinical Trials

Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab

CCTGuide Pilot
Start date: August 9, 2019
Phase: Phase 1
Study type: Interventional

Investigators will evaluate the safety, tolerability, and feasibility of a risk-guided cardioprotective treatment strategy with carvedilol, as compared to usual care, in breast cancer patients undergoing treatment with doxorubicin, trastuzumab, or the combination.

NCT ID: NCT03199300 Recruiting - Clinical trials for Cardiovascular Morbidity

Investigating Cardiovascular Adverse Events Related to Cancer Treatment

InvestiCAT
Start date: December 12, 2017
Phase:
Study type: Observational

Cisplatin, anthracyclines, bleomycin and trastuzumab can cause severe cardiovascular or pulmonary toxicity. Why some patients are susceptible to extreme toxicity of cancer treatment is largely unknown. Unraveling extreme cardiovascular toxic responses in cancer patients may help understand the pathophysiology of cardiovascular toxicity of these agents and help in understanding the more subtle, long-term cardiovascular side effects that affect a larger part of cancer survivors. With induced pluripotent stem cells we will obtain patient-derived cells to recapitulate and mimic and study pathological (cardiovascular) responses and (cardiovascular) toxicity in vitro.

NCT ID: NCT02934971 Not yet recruiting - Clinical trials for Toxicity Due to Chemotherapy

Optimized Multi-modality Machine Learning Approach During Cardio-toxic Chemotherapy to Predict Arising Heart Failure

MERMAID
Start date: January 2017
Phase: N/A
Study type: Observational

The present project will develop an automated machine learning approach using multi-modality data (imaging, laboratory, electrocardiography and questionnaire) to increase the understanding and prediction of arising heart failure in patients scheduled for cardio-toxic chemotherapy. This algorithmus will be developed by the technical cooperation partner at Technion, the institut for biomedical engineering in Haifa, Israel.

NCT ID: NCT02856048 Active, not recruiting - Cancer Clinical Trials

Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer

PRESOV
Start date: November 23, 2016
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy of a temporary ovarian suppression obtained by administration of a gonadotropin releasing hormone agonist during alkylating agents containing chemotherapy on ovarian reserve assessed by Anti-Müllerian hormone (AMH) serum levels in adolescents and young women with cancer.

NCT ID: NCT02848807 Recruiting - Quality of Life Clinical Trials

Chemotherapy-related Toxicity, Nutritional Status and Quality of Life

Start date: September 2014
Phase: N/A
Study type: Interventional

Determine whether nutritional support with high protein ONS in adult oncologic patients in the first step of cancer cachexia - asymptomatic precachexia, influence on the toxicity of systemic therapy.